What Is Mounjaro?

Mounjaro is the brand name for tirzepatide, a groundbreaking injection that mimics two key gut hormones—GIP and GLP‑1. It is FDA-approved for type 2 diabetes and recently received indication for weight loss and treatment of obstructive sleep apnoea.

How Mounjaro Works

Tirzepatide acts on both the GIP and GLP-1 receptors—offering a dual-pathway approach. This design aims to improve blood sugar control, reduce appetite, and boost insulin response.

According to Eli Lilly, Mounjaro is the first and only medicine to combine these pathways for managing diabetes in adults when paired with diet and exercise. It is available in doses from 2.5 mg to 15 mg weekly.

Approved Uses

• Type 2 Diabetes: Used alongside diet and exercise to improve glycemic control read more
• Weight Management: Now indicated for chronic obesity/overweight in adults with at least one comorbidity in Australia since late 2024 read more
• Obstructive Sleep Apnoea (OSA): Australia approves use to reduce weight and improve sleep quality

How Mounjaro Differs from Ozempic/Wegovy

• Dual-receptor action activates both GIP and GLP-1 pathways, while Ozempic and Wegovy activate only GLP-1
• Stronger weight loss: Clinical trials show average losses up to 25 percent of body weight
• Range of doses: From 2.5 mg up to 15 mg weekly, allowing for flexible treatment plans

Real-World Evidence

In a major study, participants using tirzepatide lost approximately 25 percent of body weight, often averaging around 60 pounds compared to placebo. MedicalNewsToday and Drugs.com report its effectiveness in improved glycemic control and sustained weight loss read more.

Side Effects & Safety

The most commonly reported side effects include nausea, diarrhea, constipation, vomiting and stomach discomfort pagesix.com+15drugs.com+15mayoclinic.org+15. There is a boxed warning regarding possible thyroid tumors (based on animal studies). Mounjaro is not recommended for patients with a history of medullary thyroid carcinoma or MEN 2 syndrome mayoclinic.org+15lilly.com+15en.wikipedia.org+15.

Australian patients should note that Mounjaro vials are currently in shortage until August 2025, though the KwikPen formulation is available

What to Know About Use and Dosing

• Taken by subcutaneous injection once weekly
• Dose is increased gradually, usually every 4 weeks
• Pair with diet and exercise as part of treatment plan
• Healthcare providers will monitor blood sugar, kidney and thyroid function

Mounjaro is available via private prescription only in Australia and is not funded through the PBS

Bottom Line

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 agent on the market. It offers stronger results in weight loss and glucose control than single-path drugs like Ozempic or Wegovy, though cost and availability may limit access. With proven benefits in diabetes, obesity, and sleep apnoea, it represents a shift toward multi-path hormonal support in metabolic medicine.

For deeper analysis, visit What Is Ozempic or Ozempic vs Wegovy vs Mounjaro.